🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/01/2022 | 228,13 | 231,11 | 227,26 | 228,08 | -0,23% | 1,69% | 2.214.700 |
| 20/01/2022 | 233,47 | 234,41 | 228,20 | 228,61 | -0,97% | 2,66% | 2.013.100 |
| 19/01/2022 | 231,40 | 232,66 | 230,41 | 230,84 | -0,10% | 0,97% | 1.649.300 |
| 18/01/2022 | 231,43 | 232,49 | 228,74 | 231,07 | -1,28% | 1,62% | 2.016.400 |
| 14/01/2022 | 227,00 | 234,58 | 226,59 | 234,06 | +3,30% | 3,52% | 2.178.400 |
| 13/01/2022 | 225,23 | 228,12 | 225,17 | 226,58 | +0,19% | 1,31% | 1.750.400 |
| 12/01/2022 | 225,09 | 227,19 | 223,68 | 226,14 | 0,00% | 1,56% | 1.225.000 |
| 11/01/2022 | 224,20 | 226,91 | 222,14 | 226,15 | +0,98% | 2,13% | 1.458.900 |
| 10/01/2022 | 222,91 | 225,87 | 219,10 | 223,96 | +0,95% | 3,04% | 1.844.500 |
| 07/01/2022 | 220,78 | 223,98 | 220,00 | 221,85 | +0,09% | 1,80% | 1.277.400 |
| 06/01/2022 | 221,82 | 223,99 | 221,01 | 221,65 | +0,10% | 1,34% | 1.592.900 |
| 05/01/2022 | 222,20 | 224,89 | 220,69 | 221,42 | -0,20% | 1,89% | 1.685.700 |
| 04/01/2022 | 220,73 | 222,70 | 219,11 | 221,86 | -0,30% | 1,63% | 1.384.900 |
| 03/01/2022 | 218,38 | 222,59 | 214,66 | 222,53 | +1,33% | 3,63% | 1.382.100 |
| 31/12/2021 | 222,63 | 223,50 | 219,04 | 219,60 | -1,28% | 2,00% | 1.142.000 |
| 30/12/2021 | 222,80 | 224,49 | 222,16 | 222,45 | -0,39% | 1,05% | 961.500 |
| 29/12/2021 | 221,93 | 223,95 | 221,22 | 223,32 | +0,63% | 1,23% | 726.200 |
| 28/12/2021 | 222,42 | 223,13 | 220,24 | 221,93 | -0,18% | 1,30% | 1.066.900 |
| 27/12/2021 | 223,34 | 224,20 | 220,52 | 222,34 | -0,50% | 1,65% | 2.073.400 |
| 23/12/2021 | 222,77 | 224,40 | 221,45 | 223,45 | +0,31% | 1,32% | 1.210.100 |
| 22/12/2021 | 218,60 | 223,10 | 218,27 | 222,77 | +1,91% | 2,21% | 1.436.300 |
| 21/12/2021 | 216,25 | 218,81 | 215,66 | 218,60 | +1,48% | 1,46% | 1.860.400 |
| 20/12/2021 | 215,92 | 216,39 | 213,25 | 215,41 | +0,41% | 1,45% | 1.631.600 |
| 17/12/2021 | 211,53 | 218,32 | 210,35 | 214,54 | +0,91% | 3,77% | 4.586.500 |
| 16/12/2021 | 212,05 | 214,23 | 211,11 | 212,61 | +0,70% | 1,47% | 1.964.600 |
| 15/12/2021 | 209,05 | 211,53 | 206,98 | 211,13 | +0,90% | 2,18% | 1.500.200 |
| 14/12/2021 | 208,28 | 209,99 | 206,90 | 209,24 | +0,52% | 1,48% | 1.370.100 |
| 13/12/2021 | 208,49 | 208,87 | 205,14 | 208,15 | +0,04% | 1,79% | 1.677.700 |
| 10/12/2021 | 206,70 | 208,42 | 204,11 | 208,06 | -0,17% | 2,09% | 1.371.300 |
| 09/12/2021 | 207,96 | 209,00 | 205,85 | 208,41 | +0,87% | 1,51% | 1.734.000 |